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Immunotherapy has emerged as a promising treatment
strategy for the control of HPV-associated malignancies.
Various therapeutic HPV vaccines have elicited potent
antigen-specific CD8+ T cell mediated antitumor immune
responses in preclinical models and are currently being
tested in several clinical trials. Recent evidence has
reported the importance of local immune activation, and
higher number of immune cells in the site of lesion corre-
lates with positive prognosis. Granulocyte macrophage
colony-stimulating factor (GMCSF) has been reported to
possess the ability to induce migration of antigen presenta-
tion cells and CD8+ T cells. Therefore, in the current
study, we employed a combination of systemic therapeutic
HPV DNA vaccination with local GMCSF application in
the TC-1 tumor. We show that intramuscular vaccination
with CRT/E7 DNA followed by GMCSF intravaginal
administration effectively controls TC-1 tumor in mice.
Furthermore, we observe an increase in the accumulation
of E7-specific CD8+ T cells and dendritic cells in the vagi-
nal tumor following the combination treatment. In addi-
tion, we show that GMCSF induces activation and
maturation in dendritic cells and promote antigen cross-
presentation. Our results support the clinical translation of
the combination treatment of systemic therapeutic vacci-
nation followed by local GMCSF administration as an
effective strategy for tumor treatment.
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Figure 1 (a) Survival curve analysis of four groups (b) Bioluminescence of tumor growth.
Figure 2 (a) Percentage of E7-specific CD8+ T cells in spleen and lymph node in tumor bearing mice (b) Bar graph explaining E7-specific CD8+
T cells in spleen and lymph node in tumor bearing mice
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Figure 3 (a) The number of E7-specific CD8+ T cells in cervicovaginal tumor of four groups (b) Bar graph depicting the number of E7-specific
CD8+ T cells (c) The number of IFN-y positive CD8+ T cells per 5 × 10^5 tumor cells (d) Bar graph depicting the number of IFN-y positive CD8
+ T cells per 5 × 10^5 tumor cells
Figure 4 (a) The number of dendritic cells (CD11C+CD45+) per 5 × 10^5 tumor cells (b,c) Maturation markers of dendritic cells (CD11C+CD45+)
in vaginal tumor.
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Figure 5 1 × 10^5 E7-Specific CD8 T cell were cultured together with isolated dendritic cells in 1:1 ratio for 12 hours and stained with FITC-
conjugated IFN-y and APC-conjugated CD8 followed by flow cytometry analysis (a) Representative data of IFN-y staining followed by flow
cytometry analysis showing the percentage of IFN-y positive CD8+ T cells (b) Bar graph depicting the percentage of IFN-y positive CD8+ T cells.
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